Eurofins Scientific SEFRA:ESF0 +3.31%87 EBITDA Margin % is 20.63% as of Dec. 2025, which is 5% above its 10-year median of 19.60. GuruFocus rates FRA:ESF0 with a GF Score™ of 87/100 and a GF Value™ of €66.54 (Fairly Valued). The stock has 6 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks better than 75.98% on this metric.
Eurofins Scientific SE (FRA:ESF0) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Eurofins Scientific SE EBITDA Margin % Related Terms
Eurofins Scientific SE EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Eurofins Scientific SE's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ESF0 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Eurofins Scientific SE's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE (FRA:ESF0) has a EBITDA Margin % of 20.63% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Eurofins Scientific SE and its competitors. This is near median its historical median of 19.60. Over the past decade, Eurofins Scientific SE's EBITDA Margin % has ranged from 17.37 to 25.22. According to the industry distribution chart, Eurofins Scientific SE ranks #49 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 24%.
Is Eurofins Scientific SE's EBITDA Margin % too high?
Eurofins Scientific SE's current EBITDA Margin % of 20.63% is near median its 10-year median of 19.60. Over the past 10 years, this metric has ranged from a low of 17.37 to a high of 25.22. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Eurofins Scientific SE's value of 20.63% is 296.7% above this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #49 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Eurofins Scientific SE has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #49 out of 204 companies for EBITDA Margin %. This places Eurofins Scientific SE in the top 24% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.20. Eurofins Scientific SE's value of 20.63% is 296.7% above this benchmark. Historically, Eurofins Scientific SE's own EBITDA Margin % has ranged from 17.37 to 25.22 over the past decade. While the company's 10-year median is 19.60 vs. the industry median of 5.20, Eurofins Scientific SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current EBITDA Margin % of 20.63% is 296.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current EBITDA Margin % is 20.63%, which is near median its own 10-year median of 19.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (FRA:ESF0) is currently considered Fairly Valued. The stock's GF Value™ is €66.54, compared to a current price of €64.88 — trading 2.5% below its estimated fair value. The current EBITDA Margin % is 20.63%, which is near median its 10-year median of 19.60 and 296.7% above the Medical Diagnostics & Research industry median of 5.20. Eurofins Scientific SE's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Eurofins Scientific SE (FRA:ESF0), the current EBITDA Margin % is 20.63% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (FRA:ESF0) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be undervalued.
The current stock price of €64.88 is trading 2.5% below its estimated GF Value™ of €66.54.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for FRA:ESF0:
EBITDA Margin %: 20.63% (near median its 10-year median of 19.60)
GF Value™: €66.54 vs. price of €64.88 (2.5% below fair value)
Industry Position: 296.7% above the Medical Diagnostics & Research median (#49 of 204)
No single metric tells the full story. See the FRA:ESF0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
87GF Score
Get the complete analysis for FRA:ESF0
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ESF0 has been successfully added to your 
